SCHEMBL449104

SCHEMBL449104

COC(=O)[C@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1CCC(=O)c1ccnc2ccc(OC)cc12

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.52
LMNA P02545 1/20 0.42
PIK3CD O00329 3/20 0.41
PIK3CA P42336 2/20 0.41
PIK3CB P42338 2/20 0.41
PIK3CG P48736 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PREP P48147 1/20 0.41
CYP2D6 P10635 1/20 0.41
SRC P12931 2/20 0.41
EPHX2 P34913 1/20 0.41
ABL1 P00519 1/20 0.40
EGFR P00533 1/20 0.40
ABL2 P42684 1/20 0.40
FAAH O00519 1/20 0.40
ALDH1A1 P00352 1/20 0.40
STS P08842 1/20 0.39
PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL449105 1.00 KCNH2 (0.52) KCNH2LMNAPIK3CDPIK3CAPIK3CB
SCHEMBL6705647 0.93 KCNH2 (0.59) KCNH2
SCHEMBL7728974 0.87 KCNH2 (0.50) KCNH2LMNAPIK3CDPIK3CAPIK3CB
SCHEMBL5211095 0.87 KCNH2 (0.48) KCNH2LMNAPIK3CDPIK3CAPIK3CB
SCHEMBL5185294 0.87 CYP2D6 (0.51) KCNH2LMNAKDM4ECYP2D6ALDH1A1
SCHEMBL5206227 0.87 KCNH2 (0.48) KCNH2LMNAPIK3CDPIK3CAPIK3CB
SCHEMBL446282 0.85 KCNH2 (0.57) KCNH2
SCHEMBL446283 0.85 KCNH2 (0.57) KCNH2
SCHEMBL5736765 0.79 CYP2D6 (0.49) KCNH2LMNAKDM4ECYP2D6ALDH1A1
SCHEMBL5736772 0.79 CYP2D6 (0.49) KCNH2LMNAKDM4ECYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481735-A1 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials Pfizer Inc. (US) 2012-08-01 EP disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
EP-2155716-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS Pfizer Inc. (US) 2010-02-24 EP disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 KCNH2 1203/4885LMNA 1804/4885PIK3CD 2864/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 KCNH2 1203/4885LMNA 1804/4885PIK3CD 2864/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 KCNH2 1203/4885LMNA 1804/4885PIK3CD 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.